Boston Scientific Corporation
NYSE:BSXMedical - Devices
+$0.45 today
- Market cap
- $63.25B
- Beta
- 0.56
- P/E (TTM)
- 19.0
- EPS (TTM)
- $2.39
Volume 13.21M
Average 19.45M
BSX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Boston Scientific CorporationNYSE: BSX
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) grows, but more slowly than its trailing trend
Q2 FY2026 EPS (Diluted) of $0.61 rose 15.1% year over year, behind the +46.7% change in trailing-twelve-month EPS (Diluted). Sequentially, it fell 32.2% from the prior quarter. Over 3 fiscal years it compounded at +63.3% a year.
Context
- EPS (Diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 16 analysts of $3.16 (+63.0%) for the fiscal year ending Dec 2026, a step up from the +55.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0.61-32.2% QoQ
- Last fiscal yearDec 2025
- $1.94+55.2% YoY
- LTMJun 2026
- $2.46+46.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.1% | +45.4% | +30.3 pp |
| 1 year | +55.2% | +63.0% | +7.8 pp |
| 3-year CAGR | +63.3% | +20.0% | -43.2 pp |
| 5-year CAGR | +15.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 1.94 USD
- Year-over-year change
- +55.2%
- 4-year CAGR
- +29.6%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.94 | +55.2% |
| FY2024 | 2024-12-31 | 1.25 | +16.5% |
| FY2023 | 2023-12-31 | 1.07 | +140.6% |
| FY2022 | 2022-12-31 | 0.45 | -35.1% |
| FY2021 | 2021-12-31 | 0.69 | — |
EPS (Diluted) vs competitors
How BSX compares with its peers on the latest reported figures
- BSX's LTM Jun 2026 EPS (Diluted) of $2.46 is the 5th highest of the 11 companies compared; the peer median is $1.76.
- Its year-over-year change of +46.7% is the 3rd highest of 11, against a peer median of +10.0%.
- Over three fiscal years its annual growth of +63.3% compares with a peer median of +9.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $4.07 | +8.2% | — | |
| LTM Jul 2026 | $4.06 | +11.8% | +9.8% | |
| LTM Sep 2026 | $3.5 | +187.5% | — | |
| LTM Sep 2026 | $2.66 | +36.4% | +18.2% | |
| LTM Jun 2026 | $2.46 | +46.7% | +63.3% | |
| LTM Mar 2026 | $1.77 | -53.4% | — | |
| LTM Jun 2026 | $1.74 | -75.0% | -9.1% | |
| LTM Jun 2026 | $0.21 | +127.6% | — | |
| LTM Feb 2026 | -$0.75 | +25.7% | — | |
| LTM Mar 2026 | -$2.02 | +7.3% | — | |
| LTM Jun 2026 | -$23.29 | -648.0% | — | |
| Peer median (excluding BSX) | $1.76 | +10.0% | +9.8% | |
Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B |
| Cost of Revenue | 4.43B | 4.97B | 5.41B | 6.48B | 6.22B |
| Gross Profit | 7.46B | 7.71B | 8.83B | 10.27B | 13.85B |
| Gross Margin | 62.8% | 60.8% | 62.0% | 61.3% | 69.0% |
| Research & Development | 1.2B | 1.32B | 1.41B | 1.62B | 2.05B |
| Selling, General & Admin | 4.29B | 4.52B | 5.19B | 5.98B | 6.89B |
| Operating Expenses | 5.54B | 5.89B | 6.65B | 7.63B | 9.88B |
| Depreciation & Amortization | 1.09B | 1.14B | 1.2B | 1.27B | 1.37B |
| EBITDA | 2.52B | 2.74B | 3.45B | 3.94B | 5.1B |
| EBITDA Margin | 21.2% | 21.6% | 24.2% | 23.5% | 25.4% |
| Operating Income | 1.92B | 1.82B | 2.18B | 2.64B | 3.97B |
| Operating Margin | 16.2% | 14.4% | 15.3% | 15.7% | 19.8% |
| Interest Income | 4M | 10M | 22M | 107M | 0 |
| Interest Expense | 349M | 464M | 272M | 387M | 349M |
| Other Income / Expenses | (846M) | (683M) | (196M) | (353M) | (586M) |
| Income Before Tax | 1.08B | 1.14B | 1.99B | 2.28B | 3.39B |
| Pre-Tax Margin | 9.1% | 9.0% | 13.9% | 13.6% | 16.9% |
| Income Tax Expense | 36M | 443M | 393M | 436M | 493M |
| Net Income | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
| Net Margin | 8.7% | 5.5% | 11.2% | 11.1% | 14.4% |
| EPS (Basic) | 0.69 | 0.45 | 1.08 | 1.26 | 1.96 |
| EPS (Diluted) | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| Weighted Avg Shares | 1.42B | 1.43B | 1.45B | 1.47B | 1.48B |
| Weighted Avg Shares (Diluted) | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B |
Boston Scientific Corporation
NYSE:BSX
Intrinsic Alpha fair value
Locked
Current Price
$43.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.